|
|
|
|
Former surgeon general Koop honored for AIDS work
HANOVER, N.H.(AP) Former Surgeon General Dr. Everett Koop is being honored in New Hampshire for his work on HIV and AIDS awareness and prevention. Koop on Wednesday will receive the 2010 Ryan White Distinguished Leadership Award from Indiana University's...
|
|
|
Baxter International First Quarter 2010 Financial Results Conference Call
Let the jobs come to you!Baxter International (NYSE:BAX) will host a quarterly conference call to discuss its first quarter 2010 financial results on Thursday, April 22, 2010, at 8:30 a.m! Eastern Time (7:30 a.m. Central Time). To access the call,...
|
|
|
Baxter International First Quarter 2010 Financial Results Conference Call
DEERFIELD, Ill.-- (BUSINESS WIRE) -- Baxter International (NYSE:BAX) will host a quarterly conference call to discuss its first quarter 2010 financial results on Thursday, April 22, 2010, at 8:30 a.m.Eastern Time (7:30 a.m. Central Time). To access the...
|
|
|
Former surgeon general Koop honored for AIDS work
HANOVER, N.H.(AP) Former Surgeon General Dr. Everett Koop is being honored in New Hampshire for his work on HIV and AIDS awareness and prevention. Koop on Wednesday will receive the 2010 Ryan White Distinguished Leadership Award from Indiana University's...
|
|
|
Former surgeon general Koop honored for AIDS work
HANOVER, N.H.(AP) -- Former Surgeon General Dr. Everett Koop is being honored in New Hampshire for his work on HIV and AIDS awareness and prevention. Koop on Wednesday will receive the 2010 Ryan White Distinguished Leadership Award from Indiana...
|
|
|
Former surgeon general Koop honored for AIDS work
HANOVER, N.H.(AP) - Former Surgeon General Dr. Everett Koop is being honored in New Hampshire for his work on HIV and AIDS awareness and prevention. Koop on Wednesday will receive the 2010 Ryan White Distinguished Leadership Award from Indiana University...
|
|
|
Former surgeon general Koop honored for AIDS work
HANOVER, N.H.(AP) - Former Surgeon General Dr. Everett Koop is being honored in New Hampshire for his work on HIV and AIDS awareness and prevention. Koop on Wednesday will receive the 2010 Ryan White Distinguished Leadership Award from Indiana University...
|
|
|
NewLife Homecare Partners With ChronoMed to Offer Customized Nutritional Program for Bleeding Disorder Community
PITTSTON, Pa., March 15 /PRNewswire/ -- NewLife Homecare, a leading specialty pharmacy serving people with bleeding disorders, is proud to introduce an innovative and highly-customized nutrition program for the bleeding disorder community.The program, a...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Click the browser's refresh button to reload the requested page Click the browse Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B.
|
|
|
NewLife Homecare Partners With ChronoMed to Offer Customized Nutritional Program for Bleeding Disorder Community
Companies mentioned in this article: NewLife Homecare PITTSTON, Pa., March 15 /PRNewswire/ -- NewLife Homecare, a leading specialty pharmacy serving people with bleeding disorders, is proud to introduce an innovative and highly-customized nutrition program for...
|
|
|
GTC Biotherapeutics to Webcast Corporate Presentation at the ROTH 22nd Annual OC Growth Stock Conference
- GTC Biotherapeutics, Inc.(GTC, NASDAQ: GTCB) announced today that Geoffrey Cox, Ph. D., GTC's Chairman and CEO, is scheduled to present on Wednesday, March 17, 2010 at 2:00 p.m. during the ROTH 22nd Annual OC Growth Stock Conference. The conference...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Amsterdam Molecular Therapeutics announced that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.Amsterdam, The...
|
|
|
Start Of Phase I/II Gene Therapy Clinical Trial For Hemophilia B
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
/PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for ...
|
|
|
Biogen Idec Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-11 08:17:13 - Biogen Idec Inc.- Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Biogen Idec Inc. - Pharmaceuticals & Healthcare - Deals and Alliances...
|
|
|
Medical News: Start Of Phase I/II Gene Therapy Clinical Trial For Hemophilia B
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously...
|
|
|
GTC Biotherapeutics to Webcast Corporate Presentation at the ROTH 22nd Annual OC Growth Stock Conference
Let the jobs come to you!GTC Biotherapeutics, Inc! (?GTC?, NASDAQ: GTCB) announced today that Geoffrey Cox, Ph. D., GTC?s Chairman and CEO, is scheduled to present on Wednesday, March 17, 2010 at 2:00 p.m. during the ROTH 22nd Annual OC Growth Stock...
|
|
|
GTC Biotherapeutics to Webcast Corporate Presentation at the ROTH 22nd Annual OC Growth Stock Conference
FRAMINGHAM, Mass.-- (BUSINESS WIRE) -- GTC Biotherapeutics, Inc.(GTC, NASDAQ: GTCB) announced today that Geoffrey Cox, Ph.D., GTCs Chairman and CEO, is scheduled to present on Wednesday, March 17, 2010 at 2:00 p.m. during the ROTH 22nd Annual OC Growth...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for ...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
-- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously...
|
